Key points from article :
Retro Biosciences partners with Multiply Labs for $85 million to enhance the production of cell therapies for age-related diseases.
Multiply Labs offers automation technology to streamline cell therapy production.
Retro Bio develops cell therapies to combat age-related diseases by targeting cellular drivers of aging.
Two of Retro Bio’s programs, autophagy and in vivo reprogramming, are conducted in the body.
T cell and hematopoietic stem cell reprogramming and microglia therapeutics reprogram cells in the lab and return rejuvenated cells to the body.
Multiply Labs' systems are cloud-controlled and adaptable for different therapies.
Easier integration aims to speed up automation and regulatory approvals.
“The modular structure of the Multiply Labs robots will help enable Retro to bring its unique cell therapies to patients,” said Joe Betts-LaCroix, CEO of Retro.
Both companies aim to make cell therapies more accessible and efficient.
